Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
【XinSheng Academic】Nimotuzumab Combined with Concurrent Chemoradiotherapy Significantly Improves Survival Benefits in Locally Advanced Head and Neck Squamous Cell Carcinoma
View details
→
Nimotuzumab achieves a major breakthrough in pancreatic cancer treatment; results from the Phase 3 study selected for the 2022 ASCO Oral Presentation.
The Phase III clinical trial results of nivolumab for pancreatic cancer have been selected for an ASCO oral presentation.
【XinSheng Academic】Nimotuzumab Blocks the EGFR Signaling Pathway: A Novel Strategy for COVID-19 Treatment
【XinSheng Academic】EGFR and Kras Pathways in Pancreatic Cancer: Predicting Response to EGFR Therapy
[Case Share] Issue 142: Nivolumab Treatment for Elderly Patients with Esophageal Squamous Cell Carcinoma